The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets.
H. Beltran
No relevant relationships to disclose
D. Rickman
No relevant relationships to disclose
K. Park
No relevant relationships to disclose
A. Sboner
No relevant relationships to disclose
T. Macdonald
No relevant relationships to disclose
S. T. Tagawa
No relevant relationships to disclose
M. B. Gerstein
No relevant relationships to disclose
F. Demichelis
No relevant relationships to disclose
D. M. Nanus
No relevant relationships to disclose
M. A. Rubin
No relevant relationships to disclose